Combined HAT/EZH2 modulation leads to cancer-selective cell death

Epigenetic alterations have been associated with both pathogenesis and progression of cancer. By screening of library compounds, we identified a novel hybrid epi-drug MC2884, a HAT/EZH2 inhibitor, able to induce bona fide cancer-selective cell death in both solid and hematological cancers in vitro,...

Descripción completa

Detalles Bibliográficos
Autores principales: Petraglia, Francesca, Singh, Abhishek A., Carafa, Vincenzo, Nebbioso, Angela, Conte, Mariarosaria, Scisciola, Lucia, Valente, Sergio, Baldi, Alfonso, Mandoli, Amit, Petrizzi, Valeria Belsito, Ingenito, Concetta, De Falco, Sandro, Cicatiello, Valeria, Apicella, Ivana, Janssen-Megens, Eva M., Kim, Bowon, Yi, Guoqiang, Logie, Colin, Heath, Simon, Ruvo, Menotti, Wierenga, Albertus T.J., Flicek, Paul, Yaspo, Marie Laure, Della Valle, Veronique, Bernard, Olivier, Tomassi, Stefano, Novellino, Ettore, Feoli, Alessandra, Sbardella, Gianluca, Gut, Ivo, Vellenga, Edo, Stunnenberg, Hendrik G., Mai, Antonello, Martens, Joost H.A., Altucci, Lucia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986654/
https://www.ncbi.nlm.nih.gov/pubmed/29876013
http://dx.doi.org/10.18632/oncotarget.25428

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5986654/
https://www.ncbi.nlm.nih.gov/pubmed/29876013
http://dx.doi.org/10.18632/oncotarget.25428

Ejemplares similares